There is quite a bit to like about what EX1 are doing. Give it 1-2 years for this to develop and play out and it will be over $500M in valuation.
"Up to 15 patients will receive the exosomes in the PLEXOVAL II study, which is testing the exosomes for safety and benefits in wound healing.The patients will receive Exopharm’s Plexaris exosome product following skin punch biopsies, primarily to make sure the treatment is safe. Wound closure and scarring activity will also be followed.
Plexaris is part of Exopharm’s naïve extracellular vesicle (NEV) program. Exosomes are excreted by stem cells and Exopharm says they show great promise as regenerative medicine across a range of age-related medical conditions including mobility problems such as osteoarthritis and sensory functions such as hearing loss.
With a successful outcome from PLEXOVAL II, Exopharm will be well-positioned to initiate Phase 2 studies with off-the-shelf Plexaris and Phase 1 studies with our mesenchymal stem cell EV product Cevaris."
EX1 Price at posting:
68.0¢ Sentiment: Buy Disclosure: Held
